FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Akeso keeps cadonilimab in China
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
